开云app官网登录入口网页版-官方正版

#VEGFR#

26篇内容 | 1502人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1407304, encodeId=98fe140e30486, content=<a href='/topic/show?id=d5b01834e3a' target=_blank style='color:#2F92EE;'>#VEGFR#</a>, objectTitle=J Clin Oncol：ICI联合VEGFR抑制剂治疗晚期肾细胞癌时的主要不良心血管事件风险, objectType=article, longId=300189, objectId=ad87300189e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad87300189e8, replyNumber=0, likeNumber=88, createdTime=2022-03-08, rootId=0, userName=jml2010, userId=3d8d2627959, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad87300189e8, moduleTitle=J Clin Oncol：ICI联合VEGFR抑制剂治疗晚期肾细胞癌时的主要不良心血管事件风险, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=ad87300189e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1407303, encodeId=a12f140e303a5, content=<a href='/topic/show?id=d5b01834e3a' target=_blank style='color:#2F92EE;'>#VEGFR#</a>, objectTitle=新型VEGFR抑制剂Fruquintinib治疗转移性结直肠癌：全球III期试验已经开始, objectType=article, longId=292042, objectId=cf0429204269, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf0429204269, replyNumber=0, likeNumber=62, createdTime=2021-12-18, rootId=0, userName=jml2010, userId=3d8d2627959, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf0429204269, moduleTitle=新型VEGFR抑制剂Fruquintinib治疗转移性结直肠癌：全球III期试验已经开始, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=cf0429204269)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1407302, encodeId=ec96140e302ff, content=<a href='/topic/show?id=d5b01834e3a' target=_blank style='color:#2F92EE;'>#VEGFR#</a>, objectTitle=Cancer Commun：一线VEGFR-TKI失败的mRCC患者中，二线axitinib联合抗PD-1抗体或axitinib单药治疗的疗效, objectType=article, longId=215476, objectId=dc262154e628, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc262154e628, replyNumber=0, likeNumber=64, createdTime=2021-08-10, rootId=0, userName=jml2010, userId=3d8d2627959, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc262154e628, moduleTitle=Cancer Commun：一线VEGFR-TKI失败的mRCC患者中，二线axitinib联合抗PD-1抗体或axitinib单药治疗的疗效, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=dc262154e628)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1407301, encodeId=8d8e140e3013f, content=<a href='/topic/show?id=d5b01834e3a' target=_blank style='color:#2F92EE;'>#VEGFR#</a>, objectTitle=新型VEGFR抑制剂Fruquintinib治疗转移性结直肠癌：全球III期试验已经开始, objectType=article, longId=200275, objectId=54442002e505, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=54442002e505, replyNumber=0, likeNumber=73, createdTime=2020-09-06, rootId=0, userName=jml2010, userId=3d8d2627959, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=54442002e505, moduleTitle=新型VEGFR抑制剂Fruquintinib治疗转移性结直肠癌：全球III期试验已经开始, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=54442002e505)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1407300, encodeId=b725140e3007a, content=<a href='/topic/show?id=d5b01834e3a' target=_blank style='color:#2F92EE;'>#VEGFR#</a>, objectTitle=Cell Death Dis：正反馈通路SNAIL/miR590/VEGFR/NRP1促进胃癌发生发展, objectType=article, longId=192883, objectId=fd0a1928834e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd0a1928834e, replyNumber=0, likeNumber=76, createdTime=2020-04-25, rootId=0, userName=jml2010, userId=3d8d2627959, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd0a1928834e, moduleTitle=Cell Death Dis：正反馈通路SNAIL/miR590/VEGFR/NRP1促进胃癌发生发展, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=fd0a1928834e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1407299, encodeId=da61140e2997a, content=<a href='/topic/show?id=d5b01834e3a' target=_blank style='color:#2F92EE;'>#VEGFR#</a>, objectTitle=VEGFR抑制剂Cediranib联合PARP抑制剂Lynparza治疗铂敏感复发性卵巢癌的III期试验失败, objectType=article, longId=190019, objectId=8870190019fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8870190019fe, replyNumber=0, likeNumber=65, createdTime=2020-03-16, rootId=0, userName=jml2010, userId=3d8d2627959, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8870190019fe, moduleTitle=VEGFR抑制剂Cediranib联合PARP抑制剂Lynparza治疗铂敏感复发性卵巢癌的III期试验失败, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=8870190019fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1407298, encodeId=222b140e29892, content=<a href='/topic/show?id=d5b01834e3a' target=_blank style='color:#2F92EE;'>#VEGFR#</a>, objectTitle=Sci Rep：Myoferlin沉默能够抑制VEGFR2介导的转移透明细胞肾细胞癌增殖, objectType=article, longId=179593, objectId=e0931e95934d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e0931e95934d, replyNumber=0, likeNumber=93, createdTime=2019-09-18, rootId=0, userName=jml2010, userId=3d8d2627959, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e0931e95934d, moduleTitle=Sci Rep：Myoferlin沉默能够抑制VEGFR2介导的转移透明细胞肾细胞癌增殖, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=e0931e95934d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1407297, encodeId=01bd140e297b0, content=<a href='/topic/show?id=d5b01834e3a' target=_blank style='color:#2F92EE;'>#VEGFR#</a>, objectTitle=Circulation：内皮细胞通过VEGFR2介导的旁分泌信号调节心肌生理性肥大, objectType=article, longId=167761, objectId=28c616e761c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=28c616e761c2, replyNumber=0, likeNumber=113, createdTime=2019-06-07, rootId=0, userName=jml2010, userId=3d8d2627959, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=28c616e761c2, moduleTitle=Circulation：内皮细胞通过VEGFR2介导的旁分泌信号调节心肌生理性肥大, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=28c616e761c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1407296, encodeId=ddd4140e29694, content=<a href='/topic/show?id=d5b01834e3a' target=_blank style='color:#2F92EE;'>#VEGFR#</a>, objectTitle=Front Physiol：人牙周 - 韧带干细胞的工程细胞外囊泡在骨再生期间增加VEGF / VEGFR2表达, objectType=article, longId=166771, objectId=4a7e166e7116, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a7e166e7116, replyNumber=0, likeNumber=96, createdTime=2019-05-26, rootId=0, userName=jml2010, userId=3d8d2627959, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a7e166e7116, moduleTitle=Front Physiol：人牙周 - 韧带干细胞的工程细胞外囊泡在骨再生期间增加VEGF / VEGFR2表达, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=4a7e166e7116)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1407295, encodeId=207d140e29545, content=<a href='/topic/show?id=d5b01834e3a' target=_blank style='color:#2F92EE;'>#VEGFR#</a>, objectTitle=FDA扩大了礼来的抗VEGFR2单抗Cyramza的适应症，用作肝癌患者的二线治疗, objectType=article, longId=165891, objectId=11a416589183, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=11a416589183, replyNumber=0, likeNumber=70, createdTime=2019-05-13, rootId=0, userName=jml2010, userId=3d8d2627959, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=11a416589183, moduleTitle=FDA扩大了礼来的抗VEGFR2单抗Cyramza的适应症，用作肝癌患者的二线治疗, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=11a416589183)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1407294, encodeId=d128140e2949e, content=<a href='/topic/show?id=d5b01834e3a' target=_blank style='color:#2F92EE;'>#VEGFR#</a>, objectTitle=EASL：VEGFR2单抗Ramucirumab对晚期肝细胞癌的治疗有临床益处, objectType=article, longId=164528, objectId=3745164528c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3745164528c3, replyNumber=0, likeNumber=70, createdTime=2019-04-20, rootId=0, userName=jml2010, userId=3d8d2627959, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3745164528c3, moduleTitle=EASL：VEGFR2单抗Ramucirumab对晚期肝细胞癌的治疗有临床益处, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=3745164528c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1407293, encodeId=93b9140e29337, content=<a href='/topic/show?id=d5b01834e3a' target=_blank style='color:#2F92EE;'>#VEGFR#</a>, objectTitle=DIABETOLOGIA：DPP-4抑制剂利格列汀抗血管生成作用是通过抑制氧诱导视网膜病变小鼠模型中VEGFR信号通路实现的？, objectType=article, longId=156533, objectId=8846156533e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8846156533e5, replyNumber=0, likeNumber=54, createdTime=2018-12-25, rootId=0, userName=jml2010, userId=3d8d2627959, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8846156533e5, moduleTitle=DIABETOLOGIA：DPP-4抑制剂利格列汀抗血管生成作用是通过抑制氧诱导视网膜病变小鼠模型中VEGFR信号通路实现的？, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=8846156533e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1407292, encodeId=f5c1140e292d3, content=<a href='/topic/show?id=d5b01834e3a' target=_blank style='color:#2F92EE;'>#VEGFR#</a>, objectTitle=PLos One：非小细胞肺癌中VEGFC/VEGFR3轴介导TGFβ1诱导的上皮-间质转化, objectType=article, longId=144456, objectId=870f1444563b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=870f1444563b, replyNumber=0, likeNumber=50, createdTime=2018-07-16, rootId=0, userName=jml2010, userId=3d8d2627959, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=870f1444563b, moduleTitle=PLos One：非小细胞肺癌中VEGFC/VEGFR3轴介导TGFβ1诱导的上皮-间质转化, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=870f1444563b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1407291, encodeId=bafa140e29121, content=<a href='/topic/show?id=d5b01834e3a' target=_blank style='color:#2F92EE;'>#VEGFR#</a>, objectTitle=Brit J Cancer：转移性肾细胞癌免疫组合治疗后VEGFR TKI治疗效果研究, objectType=article, longId=139220, objectId=46ac139220d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46ac139220d5, replyNumber=0, likeNumber=56, createdTime=2018-05-28, rootId=0, userName=jml2010, userId=3d8d2627959, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46ac139220d5, moduleTitle=Brit J Cancer：转移性肾细胞癌免疫组合治疗后VEGFR TKI治疗效果研究, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=46ac139220d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1407290, encodeId=07a4140e2907c, content=<a href='/topic/show?id=d5b01834e3a' target=_blank style='color:#2F92EE;'>#VEGFR#</a>, objectTitle=CLIN CANCER RES：巨噬细胞通过改变VEGFR表达促进抗VEGF治疗耐药, objectType=article, longId=121469, objectId=2c331214690e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c331214690e, replyNumber=0, likeNumber=58, createdTime=2017-11-28, rootId=0, userName=jml2010, userId=3d8d2627959, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c331214690e, moduleTitle=CLIN CANCER RES：巨噬细胞通过改变VEGFR表达促进抗VEGF治疗耐药, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=2c331214690e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1407289, encodeId=9d4c140e2893d, content=<a href='/topic/show?id=d5b01834e3a' target=_blank style='color:#2F92EE;'>#VEGFR#</a>, objectTitle=CLIN CANCER RES：HGF/c-MET通路调节非小细胞肺癌VEGFR抑制剂耐药, objectType=article, longId=113909, objectId=a3b411390971, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a3b411390971, replyNumber=0, likeNumber=66, createdTime=2017-09-25, rootId=0, userName=jml2010, userId=3d8d2627959, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a3b411390971, moduleTitle=CLIN CANCER RES：HGF/c-MET通路调节非小细胞肺癌VEGFR抑制剂耐药, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=a3b411390971)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1407288, encodeId=f46b140e28847, content=<a href='/topic/show?id=d5b01834e3a' target=_blank style='color:#2F92EE;'>#VEGFR#</a>, objectTitle=Sci Rep：PD-L1、E-cadherin、CD24和VEGFR2是上皮癌干细胞的标记并且与快速肿瘤发生相关, objectType=article, longId=112313, objectId=3530112313d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3530112313d7, replyNumber=0, likeNumber=55, createdTime=2017-09-09, rootId=0, userName=jml2010, userId=3d8d2627959, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3530112313d7, moduleTitle=Sci Rep：PD-L1、E-cadherin、CD24和VEGFR2是上皮癌干细胞的标记并且与快速肿瘤发生相关, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=3530112313d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1407287, encodeId=2772140e2870b, content=<a href='/topic/show?id=d5b01834e3a' target=_blank style='color:#2F92EE;'>#VEGFR#</a>, objectTitle=JCO：抗VEGFR-TKI耐药也不怕，卡博替尼治疗末线分化型甲状腺癌仍有很好的疗效, objectType=article, longId=110822, objectId=f90d11082200, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f90d11082200, replyNumber=0, likeNumber=59, createdTime=2017-08-26, rootId=0, userName=jml2010, userId=3d8d2627959, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f90d11082200, moduleTitle=JCO：抗VEGFR-TKI耐药也不怕，卡博替尼治疗末线分化型甲状腺癌仍有很好的疗效, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=f90d11082200)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1407286, encodeId=fa76140e286cd, content=<a href='/topic/show?id=d5b01834e3a' target=_blank style='color:#2F92EE;'>#VEGFR#</a>, objectTitle=JCO:抗VEGFR-TKI耐药也不怕，卡博替尼治疗末线分化型甲状腺癌仍有很好的疗效, objectType=article, longId=110820, objectId=ca66110820db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ca66110820db, replyNumber=0, likeNumber=70, createdTime=2017-08-26, rootId=0, userName=jml2010, userId=3d8d2627959, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ca66110820db, moduleTitle=JCO:抗VEGFR-TKI耐药也不怕，卡博替尼治疗末线分化型甲状腺癌仍有很好的疗效, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=ca66110820db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1407285, encodeId=6472140e28541, content=<a href='/topic/show?id=d5b01834e3a' target=_blank style='color:#2F92EE;'>#VEGFR#</a>, objectTitle=ASCO2017 ：VEGFR2 单抗用于复发性胶质母细胞瘤, objectType=article, longId=100862, objectId=d667100862d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d667100862d8, replyNumber=0, likeNumber=69, createdTime=2017-06-08, rootId=0, userName=jml2010, userId=3d8d2627959, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d667100862d8, moduleTitle=ASCO2017 ：VEGFR2 单抗用于复发性胶质母细胞瘤, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=d667100862d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

VEGFR

2020-05-29

jml2010 (审核中...)

前往app查看评论内容

#VEGFR#

J Clin Oncol：ICI联合VEGFR抑制剂治疗晚期肾细胞癌时的主要不良心血管事件风险

2022-03-08

jml2010 (审核中...)

前往app查看评论内容

#VEGFR#

新型VEGFR抑制剂Fruquintinib治疗转移性结直肠癌：全球III期试验已经开始

2021-12-18

jml2010 (审核中...)

前往app查看评论内容

#VEGFR#

Cancer Commun：一线VEGFR-TKI失败的mRCC患者中，二线axitinib联合抗PD-1抗体或axitinib单药治疗的疗效

2021-08-10

jml2010 (审核中...)

前往app查看评论内容

#VEGFR#

新型VEGFR抑制剂Fruquintinib治疗转移性结直肠癌：全球III期试验已经开始

2020-09-06

jml2010 (审核中...)

前往app查看评论内容

#VEGFR#

Cell Death Dis：正反馈通路SNAIL/miR590/VEGFR/NRP1促进胃癌发生发展

2020-04-25

jml2010 (审核中...)

前往app查看评论内容

#VEGFR#

VEGFR抑制剂Cediranib联合PARP抑制剂Lynparza治疗铂敏感复发性卵巢癌的III期试验失败

2020-03-16

jml2010 (审核中...)

前往app查看评论内容

#VEGFR#

Sci Rep：Myoferlin沉默能够抑制VEGFR2介导的转移透明细胞肾细胞癌增殖

2019-09-18

jml2010 (审核中...)

前往app查看评论内容

#VEGFR#

Circulation：内皮细胞通过VEGFR2介导的旁分泌信号调节心肌生理性肥大

2019-06-07

jml2010 (审核中...)

前往app查看评论内容

#VEGFR#

Front Physiol：人牙周 - 韧带干细胞的工程细胞外囊泡在骨再生期间增加VEGF / VEGFR2表达

2019-05-26

jml2010 (审核中...)

前往app查看评论内容

#VEGFR#

FDA扩大了礼来的抗VEGFR2单抗Cyramza的适应症，用作肝癌患者的二线治疗

2019-05-13

jml2010 (审核中...)

前往app查看评论内容

#VEGFR#

EASL：VEGFR2单抗Ramucirumab对晚期肝细胞癌的治疗有临床益处

2019-04-20

jml2010 (审核中...)

前往app查看评论内容

#VEGFR#

DIABETOLOGIA：DPP-4抑制剂利格列汀抗血管生成作用是通过抑制氧诱导视网膜病变小鼠模型中VEGFR信号通路实现的？

2018-12-25

jml2010 (审核中...)

前往app查看评论内容

#VEGFR#

PLos One：非小细胞肺癌中VEGFC/VEGFR3轴介导TGFβ1诱导的上皮-间质转化

2018-07-16

jml2010 (审核中...)

前往app查看评论内容

#VEGFR#

Brit J Cancer：转移性肾细胞癌免疫组合治疗后VEGFR TKI治疗效果研究

2018-05-28

jml2010 (审核中...)

前往app查看评论内容

#VEGFR#

CLIN CANCER RES：巨噬细胞通过改变VEGFR表达促进抗VEGF治疗耐药

2017-11-28

jml2010 (审核中...)

前往app查看评论内容

#VEGFR#

CLIN CANCER RES：HGF/c-MET通路调节非小细胞肺癌VEGFR抑制剂耐药

2017-09-25

jml2010 (审核中...)

前往app查看评论内容

#VEGFR#

Sci Rep：PD-L1、E-cadherin、CD24和VEGFR2是上皮癌干细胞的标记并且与快速肿瘤发生相关

2017-09-09

jml2010 (审核中...)

前往app查看评论内容

#VEGFR#

JCO：抗VEGFR-TKI耐药也不怕，卡博替尼治疗末线分化型甲状腺癌仍有很好的疗效

2017-08-26

jml2010 (审核中...)

前往app查看评论内容

#VEGFR#

JCO:抗VEGFR-TKI耐药也不怕，卡博替尼治疗末线分化型甲状腺癌仍有很好的疗效

2017-08-26

jml2010 (审核中...)

前往app查看评论内容

#VEGFR#

ASCO2017 ：VEGFR2 单抗用于复发性胶质母细胞瘤

2017-06-08

科室
- - 订阅+
  - 更多科室
工具
服务